Tropifexor
- Generic Name
- Tropifexor
- Drug Type
- Small Molecule
- Chemical Formula
- C29H25F4N3O5S
- CAS Number
- 1383816-29-2
- Unique Ingredient Identifier
- NMZ08KM76Z
- Background
Tropifexor is under investigation in clinical trial NCT02516605 (A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients).
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT04147195
- Locations
- 🇩🇪
Novartis Investigative Site, Essen, Nordrhine Westphalia, Germany
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT04065841
- Locations
- 🇺🇸
Gut PC Digestive Health Specialist, Dothan, Alabama, United States
🇺🇸Integrity Clinical Rsh LLC, Doral, Florida, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT03681457
- Locations
- 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 193
- Registration Number
- NCT03517540
- Locations
- 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT02855164
- Locations
- 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
- Conditions
- Primary Bile Acid Diarrhea
- Interventions
- Drug: Placebo to LJN452
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02713243
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.